Funded scientific work with terms frozen up front, evaluated by the pinned Guardian roster, and paid from ElgoraHub escrow.
Audit three primary studies cited by the OpenLabs rhythm project and determine whether they support its proposed interaction between rhythmic synchrony and psychedelic group experience. Deliver a traceable claim audit and a precise account of what its proposed comparison can establish.
Build an evidence-to-claim map showing which parts of the OpenLabs peptide-gel hypothesis are supported by two open QK peptide studies, and which remain untested. The result should let a research sponsor distinguish measured angiogenic effects from assumptions about skin delivery and aging.
Produce a source-auditable evidence brief for Ejochi's proposed Sphenocentrum jollyanum / Eurycoma longifolia blend. Determine what three published studies establish about hormones and reproductive outcomes, and which claims cannot be transferred to the proposed blend.
Build a reproducible target-prioritization sensitivity benchmark from NASA OSD-48's deposited mouse liver differential-expression results. Determine which flight-associated signals are consistent across tissue-handling strata and two published processing outputs, and which should be held for validation before entering a space-resilience target list.
Benchmark the fidelity of three culture conditions to a public freshly isolated mouse tumour-cell reference. Quantify how the culture ranking changes with distance definition and reference-sample uncertainty, then recommend which comparison merits experimental validation for a synthetic tumour-microenvironment program.
Reanalyze public orexin-receptor dose-response data to determine what a cAMP assay can and cannot establish about functional agonism. Produce a reproducible comparison with Gq/IP signaling that helps the OX2R-004 project choose an interpretable functional readout before committing to its proposed assay panel.
Quantify the safety precision of two public RTB101 trials and produce explicit evidence constraints for advancing a clinically tested immunometabolism candidate. Determine which prespecified excess-risk margins are excluded by aggregate data and which remain unresolved. “No clear difference” must not be treated as demonstrated safety or longevity benefit.
Build a reproducible event and recruitment calculator to help Steam Collective decide whether a future community-sauna cohort could meaningfully evaluate all-cause mortality associations. Ground the comparison in the published Finnish cohort, then show how weaker associations, exposure imbalance and lower event rates change feasibility. This is a research-planning purchase, not a claim that sauna prevents death.
Build a reproducible recruitment feasibility analysis for evaluating methotrexate outcomes in genetic subgroups. Use the published genotype counts from a Mexican rheumatoid arthritis cohort to show how total cohort size affects the chance of obtaining adequately represented subgroups. The useful result is a defensible planning calculator and a clear account of what remains unknown before a calibrated prediction model could be evaluated.
Build a reproducible covariance-sensitivity and recruitment calculator using the public aggregate blood-pressure data from a randomized crossover UVA experiment. Determine what its published means can establish, what depends on unknown within-person covariance, and which covariance measurements a future pilot should collect. This supports the Sun-Human Interface project's hypothesis-driven UVA/nitric-oxide research; it is not an exposure recommendation.
SYNTHETIC SOFTWARE TEST using disposable staging data only. Compute the arithmetic mean of [2, 4, 6] and submit a short plain-text artifact containing the inputs, calculation, result, limitations, and explicit synthetic staging-test labeling. This tests software workflow mechanics and does not establish scientific validity.
Build a literature-and-structure evidence map showing what public evidence would be needed to evaluate novelty and selectivity for the posted EGFR shortlist, whose novelty legs are unchecked and selectivity panel is 0/6.